Clinical trials referenced in this document:
Funding for this research was provided by:
Received: 13 April 2021
Accepted: 14 July 2021
First Online: 31 July 2021
: Informed consent was not required, as the data were collected for clinical and administrative purposes and were analysed after de-identification. Analyses of data were conducted in accordance with local laws and regulations, and received approvals from Scientific/Ethics/Data Protection Committees in each country. Country-specific analyses were conducted by independent academic/statistical groups in each country.
: Not applicable.
: KK reports grants from AstraZeneca, during the conduct of the study; grants from Amgen, grants from AstraZeneca, grants from Bayer, grants from NAPP, grants from Lilly, from Merck Sharp & Dohme, personal fees from Novartis, personal fees from Novo Nordisk, personal fees from Roche, personal fees from Berlin-Chemie AG/Menarini Group, personal fees from Sanofi-Aventis, personal fees from Servier, personal fees from Boehringer Ingelheim, grants from Pfizer, grants from Boehringer Ingelheim, grants from AstraZeneca, grants from Novartis, grants from Novo Nordisk, grants from Sanofi-Aventis, grants from Lilly, grants from Merck Sharp & Dohme, grants from Servier, outside the submitted work.SK has received grants from Bayer Yakuhin and Daiichi Sankyo and consulting fees from Bayer Yakuhin, Bristol-Myers Squibb, and Pfizer.CSPL has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC; and serves as co-founder & non-executive director of Us2.ai.MAC reports research support to his institution from Amgen, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis; consulting fees from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Boston Scientific, Edwards Lifesciences, Merck, Novo-Nordisk.AN has received personal fees from AstraZeneca for this study, and honorarium for lectures and advisory board meetings for Novo Nordisk, Boehringer Ingelheim, and Lilly.MEJ is a shareholder of Novo Nordisk. MEJ has received grants from AstraZeneca, Amgen, Boehringer Ingelheim and Sanofi Aventis.RWH has received grants to his institution from AstraZeneca.JF-N has received grants to his institution from AstraZeneca for this study and has received honoraria for lectures and consulting from Novartis, NovoNordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme.NT has received consulting fees from Otsuka, Tricida, BI-Lilly, Janssen and AstraZeneca. He has received research support from AstraZeneca, Otsuka and Janssen, including for this work. He owns stock in Tricida, Pulsedata, Mesentech and Renibus. His research program is supported by the Canadian Institute for Health Research and Research Manitoba.JES has received honoraria for advisory boards and lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mylan, Novartis, Novo Nordisk, Pfizer, and Sanofi.AK has received grants and consulting fees from AstraZeneca, Novo Nordisk, Merck, and Boheringer Ingelheim.S-YG has received institutional grants from AstraZeneca, Medtronic, and Sanofi. He has participated in advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Medtronic and Sanofi and has received honoraria for participation.C-EC has received honorarium from AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi.JGE has received honorarium for lectures and advisory board meetings for Novo Nordisk, Boehringer Ingelheim, and AstraZeneca.FZ has received honoraria for lectures from Napp Pharmaceuticals and Boehringer Ingelheim.DM has received grants to her institution from AstraZeneca.MT is an employee at Statisticon for which AstraZeneca is a client.HC, EW, JS, FS and PF are AstraZeneca employees and hold stock options. JB is a AstraZeneca employee.MK has received research grants from AstraZeneca and Boehringer Ingelheim, has served on advisory boards for AstraZeneca, Boehringer Ingelheim, Sanofi, Glytec, Novo Nordisk, ZS Pharma, Janssen, Merck (Diabetes) and Novartis; consultant for AstraZeneca, Boehringer Ingelheim, Sanofi, GSK, Janssen, Intarcia, Merck (Diabetes), Novo Nordisk, Glytec and ZS Pharma.